CCS
APLS

Concentric Capital Strategies’s Apellis Pharmaceuticals APLS Stock Holding History

Concentric Capital Strategies’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,979
Closed -$407K – 257
2025
Q3 		$407K Buy
+17,979
New +$419K 0.02% 274

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Concentric Capital Strategies's APLS Position: Q4 2025 in Review

Concentric Capital Strategies sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 17,979 shares — an estimated $407K sold.

Concentric Capital Strategies first reported a position in APLS in Q3 2025 and held it in 1 quarter. The position peaked at $407K in Q3 2025. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • Concentric Capital Strategies reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Concentric Capital Strategies sold 17,979 Apellis Pharmaceuticals shares in Q4 2025, an estimated $407K.
  • Concentric Capital Strategies first reported a position in Apellis Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Concentric Capital Strategies's Apellis Pharmaceuticals position peaked at $407K in Q3 2025.
  • 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on Concentric Capital Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.